Skip to main content
Glama

Dst Dk

by io.github.pipeworx-io

Resolve Entity

resolve_entity
Read-onlyIdempotent

"What's the ticker for…" / "find the CIK for…" / "what's the LEI for…" / "what's the RxCUI for…" / "look up the ID for…" / "what is X's official identifier" / "who owns X" / "is X a subsidiary of Y" — resolve a user-spoken NAME to the canonical/official identifiers other tools require as input. Use FIRST whenever you have a name but need an ID. SUPPORTED TYPES: "company" (cross-source identity spine: 10-digit CIK + ticker + company_name from SEC EDGAR, legal-entity LEI from GLEIF with parent/ultimate-parent/children ownership when the LEI resolves, and security FIGI from OpenFIGI — by exact ticker map when a ticker is implied, and otherwise by name search, so NON-EQUITY instruments that never have a ticker (municipal and corporate bonds, notes, authority debt) DO resolve here; when a name matches more than one instrument it asserts nothing and returns figi_candidates to pick from, which is the correct answer to an issuer name that does not identify a single bond; every identifier is labelled with the source that established it, and an identifier that could NOT be resolved is stated explicitly under unresolved rather than omitted — accepts ticker, CIK, ISIN, or company name as input; an ISIN like "CH0038863350" resolves to the LEGAL ENTITY that issued the security via the GLEIF ISIN-to-LEI mapping, covering non-US issuers EDGAR cannot reach), "drug" (returns RxCUI + ingredient + brand from RxNorm + pipeworx://rxnorm/concept/{rxcui} citation; accepts brand or generic name). LEI/FIGI enrichment degrades gracefully — if GLEIF or OpenFIGI is unavailable, the EDGAR identifiers still return. Each call cascades through several lookup endpoints internally — using resolve_entity replaces 2-3 manual lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valueYesFor company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., "ozempic", "metformin"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed ("NEW YORK ST DORM AUTH"), never the question's full noun phrase ("NEW YORK ST DORM AUTH revenue bonds"): the FIGI lookup matches instrument names, so trailing security-class words match nothing.

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Changed1 schema field changed
    • changedInput schema / properties / value / description
      Previous value: -"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\")."New value: +"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed (\"NEW YORK ST DORM AUTH\"), never the question's full noun phrase (\"NEW YORK ST DORM AUTH revenue bonds\"): the FIGI lookup matches instrument names, so trailing security-class words match nothing."
  2. First observed

TDQS

A4.7/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already declare the tool read-only and idempotent, and the description adds substantial behavioral context: internal cascading lookups, graceful degradation when GLEIF/OpenFIGI are unavailable, explicit `unresolved` reporting, and returning `figi_candidates` when a name is ambiguous. These are genuinely useful beyond the annotation hints.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is dense and long, but it front-loads the primary purpose and usage instruction. While some sentences are verbose and could be tightened, virtually every clause adds a necessary edge case or supported-type detail for a non-trivial tool.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

Given the tool's complexity and lack of output schema, the description covers inputs, supported types, resolved identifiers, source systems, ambiguity behavior, unresolved results, and degradation scenarios. An agent has enough information to invoke it correctly and anticipate the shape of results.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema coverage is 100%, so the baseline is 3, but the description adds significant semantic value for the `value` parameter. It clarifies the input should be the entity name only, warns against including full noun phrases for bonds, and gives concrete examples across ticker, CIK, ISIN, drug brand, and generic names.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description states a clear, specific purpose: resolve a user-spoken name to the canonical identifiers other tools need. It enumerates concrete example user questions and supported entity types (company and drug), which distinguishes it from likely siblings like entity_profile and compare_entities.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description explicitly says to use this tool whenever you have a name but need an ID, and front-loads that guidance with realistic phrasings. It does not explicitly name alternative tools or state when not to use it, but the context is clear enough for an agent to route correctly.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

All Dst Dk toolsInspect
Try in Browser
RayrunBuild, deploy, and operate MCP servers without becoming an infrastructure team.ray.runAd

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.6/5.0
Disambiguation2/5

Several tools have overlapping functionality, especially in the ask_pipeworx family (ask_pipeworx, ask_pipeworx_beta, ask_pipeworx_grounded) and the polymarket group (bet_research, polymarket_edges, etc.). Descriptions acknowledge these overlaps, making it difficult for an agent to choose the correct tool without deep understanding.

Naming Consistency2/5

Naming conventions are inconsistent: some tools use snake_case (ask_pipeworx, bet_research), others use camelCase or PascalCase (ai_visibility_check, generate_llms_txt, polymarketArbitrage?). Also, tools like 'list_subjects' and 'get_data' have no clear pattern with the rest.

Tool Count2/5

With 35 tools, the server feels overloaded and tries to cover too many distinct domains (data queries, prediction markets, subscriptions, memory, national statistics). This broad scope reduces coherence and makes the tool set harder to navigate.

Completeness3/5

The tool set covers a wide range of capabilities, from data retrieval to prediction market analysis and subscription management. However, the inclusion of Denmark-specific statistics tools (e.g., list_subjects, get_data) seems out of place and creates a niche gap for users interested in other national datasets.

Resources